Question 1

What is Loncastuximab tesirine?

Accepted Answer

Loncastuximab tesirine is a Other.

Question 2

How often does Loncastuximab tesirine appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Loncastuximab tesirine first tracked by Ergen?

Accepted Answer

First tracked on Jun 11, 2026.

Question 4

When was Loncastuximab tesirine last mentioned in news?

Accepted Answer

Last active on Jun 28, 2026.

Question 5

What is Loncastuximab tesirine's current news sentiment?

Accepted Answer

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Loncastuximab tesirine in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Loncastuximab tesirine?

Accepted Answer

ADC Therapeutics faces fraud investigation (Jun 11, 2026, 6 articles).

Question 8

How did the "ADC Therapeutics faces fraud investigation" event impact Loncastuximab tesirine?

Accepted Answer

Loncastuximab tesirine, a drug developed by ADC Therapeutics, showed disappointing results in its Phase 3 LOTIS-5 trial, leading to a significant drop in ADC Therapeutics' stock price and a securities fraud investigation.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.